StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 40 full-time employees. The company is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The firm offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.
最新の財務諸表(Form-10K)によると、StageZero Life Sciences Ltdの総資産は$0で、純損失は$-11です。
SZLSFの主要な財務比率は何ですか?
StageZero Life Sciences Ltdの流動比率は0、純利益率は-366.66、1株当たり売上高は$0.02です。
StageZero Life Sciences Ltdの収益はセグメントまたは地域別にどのように分けられていますか?
StageZero Life Sciences Ltd の最大収益セグメントは Hospitals and Ambulatory Surgery Centers で、最新の利益発表における収益は 22,660,047 です。地域別に見ると、United States が StageZero Life Sciences Ltd の主要市場であり、収益は 24,060,337 です。
StageZero Life Sciences Ltdは収益を上げていますか?
いいえ、最新の財務諸表によると、StageZero Life Sciences Ltdの純損失は$-11です。